Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine for Renal Function in Chronic Hepatitis B with CKD
NCT02049736Withdrawn
- Sponsor
- The Chinese University of Hong Kong
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label, single-arm trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by The Chinese University of Hong Kong. Primary endpoint: change in estimated glomerular filtration rate. Planned start Dec 2013; status: withdrawn.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02049736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049736.